Crohn's Disease - Current views on Aetiology and its Impact on Management

Abstract

Get full access to this article

View all access options for this article.

References

Dalziel

. Chronic interstitial enteritis BMJ 1913; 2:1068–70.

Crohn

Ginzburg

Oppenheimer

. Regional enteritis: a pathological and clinical entity. JAMA 1932; 99:1323.

Binder

Booth

Hansen

. Incidence and prevalence of ulcerative colitis and Crohn's disease in the county of Copenhagen 1962–1978. Gastroenterology 1982; 83:563–8.

Stonnington

Phillips

Melton

Zinsmeister

. Chronic ulcerative colitis: incidence and prevalence in a community. Gut 1987; 28:402–9.

Harries

Baird

Rhodes

Mayberry

. Has the rising incidence of Crohn's disease reached a plateau? BMJ 1982; 284:235.

Kyle

Stark

. Fall in the incidence of Crohn's disease. Gut 1980; 21:340–3

Acheson

. The distribution of ulcerative colitis and regional enteritis in United States veterans with particular reference to the Jewish religion. Gut 1960; 1:291–3.

Keighley

Miller

Hughes

Leyman

. The demographic and social characteristics of patients with Crohn's disease in the Nottingham area. Scand J Gastroentrol 1976; 11:293–6.

Norlen

Krause

Bergman

. An epidemiological study of Crohn's disease. Scand J Gastroenterol 1970; 5:385–90.

10.

Hellers

. Crohn's disease in Stockholm county 1955–1974. A study of epidemiology, results of surgical treatment and long term prognosis. Acta Chirugica Scandinavia 1979; 490:1–84.

11.

Jewell

. Crohn's disease. Medicine International 1994; 22:321.

12.

Allan

. Gastroenterology. In: Bouchier

Allen

Hodgeson

Keighly

(eds). Clinical science and practice, 2nd edition vol 2. WB Saunders, 1993.

13.

Forbes

. Clinicians guide to inflammatory bowel disease. London:Arnold, 1997.

14.

Bhatti

Chapman

Peters

. Radioimmunoscintigraphy with III-indium labelled monoclonal anti-E-selectin antibody and circulating soluble E-selectin in the evaluation of inflammatory bowel disease. Gastroenterology 1996; 110:A864.

15.

Seldenrijk

Drexhage

Meuwissen

Mesjer

. T cellular immune reactions (in macrophage inhibition factor assay) against mycobacterium paratuberculosis, mycobacterium kansasii, mycobacterium tuberculosis, mycobacterium axium in patients with chronic inflammatory bowel disease. Gut 1990; 31:529–35.

16.

Kreuzpaintner

Kirschner

Wallner

. Mycobacteria of Runyon groups I, II and IV do not play an aetiological role in Crohn's disease. Eur J Gastroenterol Hepatol 1995; 12:1177–82.

17.

Rowbotham

Mapstone

Tredosiewicz

. Mycobacterium paratuberculosis DNA not detected in Crohn's disease tissue by fluorescent polymerase chain reaction. Gut 1995; 5:660–7.

18.

Ibbotson

Lowes

Chahal

. Mucosal cell mediated immunity to mycobacterial, enterobacterial and other microbiol antigens in inflammatory bowel disease. Clin Exp Immunol 1992; 87:224–30.

19.

Hampson

Parker

Saverymuttush

. Quadruple antimycobacterial chemotherapy in Crohn's disease: results at 9 months of a pilot study in 20 patients. Ailment Pharmacol Ther 1989; 3:343–52.

20.

Paris

Simon

Paris

. Critical study of the effects of antitubercular medication in a series of 18 cases of severe forms of Crohn's disease. (Article in French) Lille Med 1975; 20:333–41.

21.

Picciotto

Gesu

Schito

. Antimycobacterial chemotherapy in two cases of inflammatory bowel disease. Lancet 1988; 1:536–7.

22.

Schultz

Rieder

Hersh

Riepe

. Remission of Crohn's disease with antimycobacterial chemotherapy. Lancet 1987; 2:1391–2.

23.

Thayer

Coutu

Chiodini

. Possible role of mycobacteria in inflammatory bowel disease. II. Mycobacterial antibodies in Crohn's disease. Dig Dis Sci 1984; 29:1080–5.

24.

Toulet

Rousselet

Viteau

. Rifampicin in the treatment of Crohn's disease. (Article in French) Gastroentrol Clin Biol 1979; 3:209–10.

25.

Warren

Rees

Cox

. Remission of Crohn's disease with tuberculosis chemotherapy. N Engl J Med 1986; 314:182.

26.

Elliot

Burnham

Berghouse

. Sulphadoxine-pyrimethamine therapy in Crohn's disease. Digestion 1982; 23:132–4.

27.

Swift

Srivastava

Stone

. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut 1994; 35:363–8.

28.

Shaffer

Hughes

Linaker

. Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut 1984; 25:203–5.

29.

Thomas

Swift

Green

. Controlled trial of anti-tuberculous chemotherapy in Crohn's disease: a five year follow-up study. Gut 1998; 42:497–500.

30.

Tysk

Lindberg

Jarneret

Floderus-Myrhed

. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dyzygotic twins. A study of heritability and the influence of stricturing. Gut 1988; 29:990–6.

31.

Roth

Petersen

McElree

. Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews. Gastroenterology 1989; 96:1016–20.

32.

Satsangi

Parkes

Louis

. Two stage genome-wide search in inflammatory bowel disease: evidence for susceptibility loci on with chromosomes 3, 7 and 12. Nat Genet 1996; 14:199–202.

33.

Futami

Aoyama

Honsako

. HLA-DRB1*1502 allele subtype of DRI5 is associated with susceptibility to ulcerative colitis and its progression. Dig Dis Sci 1995; 40:814–8.

34.

Toyoda

Wang

S-J

Yang

Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993; 104:741–8.

35.

Satsangi

Welsh

Bunce

. Contribution of genes of the major histocompatability complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996; 347:1212–7.

36.

Gendler

Spicer

. Epithelial mucous genes. Ann Rev Physiol 1995; 57:610–34.

37.

Tysk

Riedesel

Lindsberg

. Colonic glycoproteins in monozygotic terms with inflammatory bowel disease. Gastroenterology 1991; 100:419–23.

38.

Elson

Sartor

Tennyson

Riddell

. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109:1344–67.

39.

Brauer

Gee

Grace

Thompson

ABR

. Diet of women with Crohn's and other gastrointestinal diseases. J Am Dietic Assoc 1983; 82:659–64.

40.

James

Graham

Torance

Taylor

. Breakfast and Crohn's disease. BMJ 1978; 2:1715–6.

41.

Jarnerot

Jarnmark

Nilsson

. Consumption of refined sugar in patients with Crohn's disease, ulcerative colitis or irritable bowel syndrome. Scand J Gastroenterol 1983; 18:999–1002.

42.

Berghouse

Hori

Hill

. Comparison between bacterial and oligosaccharide content of ileostomy effluent in subjects taking diets rich in refined and unrefined carbohydrates. Gut 1984; 25:1071–7.

43.

Lesko

Kaufman

Rosenberg

. Evidence for an increased risk of Crohn's disease in oral contraceptive users. Gastroenterol 1985; 89:1046–9.

44.

Vessey

Jewell

. Chronic inflammatory bowel disease, cigerette smoking and use of oral contraceptive: findings in a large cohort study of women of childbearing age. BMJ 1986; 292:1101–3.

45.

Cope

Heatley

Kelleher

Lee

. Cigarette smoking and inflammatory bowel disease: a review. Hum Toxicol 1981; 6:189–93.

46.

Harries

Jones

Heatley

Rhodes

. Smoking habits and inflammatory bowel disease: effect on nutrition. BMJ 1982; 284:1161.

47.

Katschinski

Logan

Edmond

Langman

. Smoking and sugar intake are separate but interactive risk factors in Crohn's disease. Gut 1988; 29:1202–6.

48.

Soltis

Hasz

Morris

Wilson

. Evidence against the presence of antibody immune complexes in chronic inflammatory bowel disease. Gastroenterology 1979; 76:1380–5.

49.

Thornton

Emmett

Heaton

. Smoking, sugar and inflammatory bowel disease. BMJ 1985; 290:1786–7.

50.

Daszak

Purcell

Lewin

. Detection and comparative analysis of persistent measles virus in Crohn's disease by immunogold electron microscopy. J Clin Pathol 1997; 50:299–304.

51.

Haga

Funakoshi

Kuroe

. Absence of measles virus genomic sequence in intestinal tissues from Crohn's disease by nested polymerase chain reaction. Gut 1996; 38:211–5.

52.

Fisher

Yee

Nightingale

. Measles virus serology in Crohn's disease. Gut 1997; 41:66–9.

53.

Ekbom

Wakefield

Zack

Adami

. Perinatal measles infection and subsequent Crohn's disease. Lancet 1994; 344:5108–10.

54.

Thompson

Montgomery

Pounder

Wakefield

. Is measles vaccination a risk factor for inflammatory bowel disease? Lancet 1995; 345:1071–4.

55.

Shaheen

Aaby

Hall

. Measels and atopy in Guinea-Bissau. Lancet 1996; 347:1792–6.

56.

Wakefield

Sawyerr

Dhillon

. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989; 2:1057–62.

57.

Wakefield

Sankey

Dhillon

. Granulomatous vasculitis in Crohn's disease. Gastroenterology 1991; 100:1279–87.

58.

Hollander

Vadheim

. Brettholz E et al. Increased intestinal permeability in patients with Crohn's disease and their relatives. Ann Intern Med 1986; 105:883–5.

59.

Katz

Hallander

Vadheim

. Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 1989; 97:927–31.

60.

May

Sutherland

Meddings

. Is small intestinal permeability really increased in relatives of patients with Crohn's disease? Gastroenterology 1993; 104:1627–32.

61.

Radford-Smith

Jewell

. Cytoklines and inflammatory bowel disease. Baillieres Clin Gastroenterol 1996; 10:151–64.

62.

Woywodt

Neustock

Kruse

. Cytokine expression in intestinal mucosal biopsies. In situ hybridisation of the nRNA for interleukin-1 beta, interleukin-6 and tumour necrosis factor-alpha in inflammatory bowel disease. Eur Cytokine Netw 1994; 5:387–95.

63.

Kucharzik

Lugering

Weigelt

. Immunology properties of ILI3 patients with inflammatory bowel disease; comparison with IL4 and IL-10. Clin Exp Immunol 1996; 104:483–90.

64.

Koizumi

King

Lobb

. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 1992; 103:840–7.

65.

Jones

Barts

Haider

. Adhesion molecules in inflammatory bowel disease. Gut 1995; 36:724–30.

66.

Nielson

Langholz

Hendel

Brynskov

. Circulating soluble intercelluler adhesion molecule 1 (sICAM) in active inflammatory bowel disease. Dig Dis Sci 1994; 39:1918–23.

67.

Pooley

Ghosh

Sharon

. Up regulation of E-selection and intercellular adhesion molecule-1 differs between Crohn's disease and ulcerative colitis. Dig Dis Sci 1995; 40:219–25.

68.

Rachmilewitz

Eliakim

Sinom

. Cytokines and platelet activating factor in human inflamed colonic mucosa. Agents Actions 1992; Spec No:C32–6.

69.

Sobhani

Hochlaf

Denizot

. Raised concentrations of platelet activating factor in colonic mucosa of Crohn's disease patients. Gut 1992; 33:1220–5.

70.

Travis

Jewell

. The role of platelet activating factor in pathogenesis of gastrointestinal disease. Prostaglandins Leukot Essent Fatty Acids 1994; 50:105–13.

71.

Schmidt

Baumieister

Kipnowski

. Alteration of prostaglandin E2 and leukotrines B4 synthesis in chronic inflammatory bowel disease. Hepatogastroenterology 1996; 43:1508–12.

72.

Kim

Tagari

Griffiths

. Levels of peptidoleukotriene E4 are elevated in active Crohn's disease. J Pediatr Gastroenterol Nutr 1995; 20:403–7.

73.

Casellas

Guarner

Antolin

. Abnormal leukotriene C4 released by unaffected jejunal mucosa in patients with inactive Crohn's disease. Gut 1994; 35:517–22.

74.

McKenzie

Baker

Buffington

Doe

. Evidence of oxidant-induced injury to epithelial cells during inflammatory disease. J Clin Invest 1996; 98:136–41.

75.

Buffington

Doe

. Depleted mucosal antioxidant defences in inflammatory bowel disease. Free Radic Biol Med 1995; 19:911–8.

76.

Solis-Herruzo

Fernandez

Vilalta-Castelle

. Diminished cytochrome b content and toxic oxygen metabolite production in circulating neutrophils from patients with Crohn's disease. Dig Dis Sci 1993; 38:1631–7.

77.

Caesar

Gross

Roth

. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified release budesonide. German Budesonide Study Group. Hepatogastroenterology 1997; 44:445–51.

78.

Gross

Andus

Caesar

. Oral pH modified release budesonide versus 6 methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. Eur J Gastoenterol Hepatol 1996; 8:905–9.

79.

Lofberg

Rutgeerts

Malchow

. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo-controlled one year study. Gut 1996; 39:82–6.

80.

Spencer

McTavish

. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 1995; 50:854–72.

81.

Greenberg

Feagan

Martin

. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331:836–41.

82.

Arber

Odes

Fireman

. A controlled double blind multicentre study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. J Clin Gastroenterol 1995; 20:203–6.

83.

Messori

Brignola

Trallori

. Effectiveness of 5–aminosalicylic acid for maintaining remission in patients with Crohn's disease; a meta-analysis. Am J Gastroentrol 1994; 89:692–8.

84.

Thomson

Wright

Vatn

. Mesalazine (Mesasal/Claversal) 1.5 g bd vs placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ther 1995; 9:673–83.

85.

Green

Holdsworth

Lobo

. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group Gastroenterology 1998; 114:15–22.

86.

Papadopoulou

Rawashdeh

Brown

. Remission following an elemental diet or prednisolone in Crohn's disease. Acta Paediatr 1995; 84:79–83.

87.

King

Woolner

Hunter

. Review article: the dietary management of Crohn's disease. Aliment Pharmacol Ther 1997; 11:17–31.

88.

Kelly

Fleming

. Nutritional consideration in inflammatory bowel disease. Gastroenterol Clin North Am 1995; 24:597–611.

89.

Sutherland

Singleton

Sessions

. Double blind placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32:1071–5.

90.

Rutgeerts

Hiele

Geboes

. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108:1617–21.

91.

Duffy

Daum

Fisher

. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985; 88:681–4.

92.

Santos

Baudet

Casellas

. Intravenous cyclosporine for steroid refractory attacks of Crohn's disease. Short and long term results. J Clin Gastroenterol 1995; 20:207–10.

93.

Stange

Modigliani

Pena

. European trial of cyclosporine in chronic active Crohn's disease: a 12 month study. The European Study Group. Gastroenterology 1995; 109(3):1001–3.

94.

Sandborn

Tremaine

Lawson

. Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose cyclosporine. Am J Gastroenterol 1996; 91:37–43.

95.

Lobo

Juby

Rothwell

. Long term treatment of Crohn's disease with cyclosporin. The effect of a very low dose on maintenance of remission. J Clin Gastroenterol 1991; 13:42–5.

96.

Lemann

Chamiot-Prieur

Mesnard

. Methotrexate for the treatment of refractory Crohn's disease. Aliment Pharmacol Ther 1996; 3:309–14.

97.

Feagan

Rochon

Fedorak

. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Eng J Med 1995; 332:292–7.

98.

van Dullemen

van Deventer

Hommes

. Treatment of Crohn's disease with anti- tumour necrosis factor chimeric monoclonal antibody (CAZ). Gastroenterology 1995; 109:129–35.

99.

Sandborn

. A controlled trial of anti-tumour necrosis factor alpha antibody for Crohn's disease. Gastroenterology 1997; 113:1042–3.

100.

van Hogezand

Verspaget

. Selective immunomodulation in patients with inflammatory bowel disease - future therapy or reality? Neth J Med 1996; 48:64–7.

101.

Reimund

Dumont

Muller

. In vitro effects of oxypentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 1997; 40:475–80.

102.

Bauditz

Haemling

Ortner

. Treatment with tumour necrosis factor inhibitor oxyentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 1997; 40:470–4.

103.

van Deventer

Elson

Fedoral

. Multiple doses of intravenous interleukin 10 in steroid refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997; 113:383–9.

104.

Stronkhorst

Radema

Yong

. CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding survey. Gut 1997; 40:320–7.

105.

Canva-Delacambre

Jacquot

Robinet

. Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody. Aliment Pharmacol Ther 1996; 10:721–7.

106.

Shoda

Matsueda

Yamato

Umeda

. Therapeutic efficacy of N3 polyunsaturated fatty acid in experimental Crohn's disease. J Gastroenterol 1995; 30(Suppl 8):98–101.

107.

Hawkey

Mahida

Hawthorne

. Therapeutic interventions in gastrointestinal disease based on an understanding of inflammatory mediators. Agents Actions 1992; Spec No C22–6.

108.

Stack

Mann

Roy

. Randomized control trial of CDP 571 antibody to tumour necrosis facto-alpha in Crohn's disease. Lancet 1997; 349:521–4.

109.

Belluzi

Brigada

Campieri

. Effect of an enteric coated fish oil preparation in relapses in Crohn's disease. N Engl J Med 1996; 334:1557–60.